In 2005, Dr. Powderly founded Carolina BioOncology Institute (CBOI), a community based clinic in Huntersville NC and is the only independent phase I cancer center with a Human Applications Lab for manufacturing cellular therapies. CBOI has opened > 160 early phase clinical trials and serves as a regional referral hub for Phase I access. Dr. Powderly’s research on early phase immunotherapy research has led to > 100 publications & abstract presentations, including the New England Journal of Medicine, Journal of Clinical Oncology, Journal of Immunotherapy, Nature, Clinical Cancer Research, Clinical Chemistry, Investigational New Drugs, Science Translational Medicine. He has also a reviewer for multiple cancer journals, NIH grant reviewer, and is currently adjunct Clinical Assistant Professor of Medicine at both Duke and UNC. In 2014 he was awarded the David King Community Scientist Award by the Association of Community Cancer Centers (ACCC). Some of his articles and presentations have been recognized as “top 50 most cited articles by JCO” and “top 10 most downloaded ASCO Video Presentations", and New York Presbyterian Hospital "2015 Herbert Pardes Clinical Research Excellence Award." Dr. Powderly’s research publications have been cited by >27,000 references in the scientific literature. He is currently also developing an autologous adaptive immune cell therapy (AAICT) platform with BioCytics Inc, using autologous circulating tumor cells as the antigen source for ex-vivo antigen presentation.